

## New Drug Approvals

### Generic Name (Trade Name) Company

June 8, 2018

### Venetoclax

### Uses/Notes

[FDA granted regular approval](#) to venetoclax for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

Approval was based on MURANO, a randomized (1:1), multicenter, open-label trial of venetoclax with rituximab (VEN+R) versus bendamustine with rituximab (B+R) in 389 patients with CLL who had received at least one prior line of therapy. Patients in the VEN+R arm completed a 5-week ramp-up venetoclax schedule and then received venetoclax 400 mg once daily for 24 months measured from the rituximab start date.

Rituximab was initiated after venetoclax ramp-up and given for six cycles (375 mg/m<sup>2</sup> intravenously on cycle 1, day 1 and 500 mg/m<sup>2</sup> intravenously on day 1 of cycles 2–6, with a 28-day cycle length). The comparator arm received six cycles of B+R (bendamustine 70 mg/m<sup>2</sup> on days 1 and 2 of each 28-day cycle and rituximab at the above described dose and schedule).

Efficacy was based on progression-free survival (PFS) as assessed by an independent review committee. After a median follow-up of 23 months, the median PFS was not reached in the VEN+R arm and was 18.1 months (95% CI 15.8–22.3) in the B+R arm (hazard ratio [HR] 0.19 [95% CI 0.13–0.28]; *P*

In patients treated with VEN+R, the most common adverse reactions (incidence ≥20%) were neutropenia, diarrhea, upper respiratory tract infection, fatigue, cough, and nausea. Grade 3 or 4 neutropenia developed in 64% of these patients, and grade 4 neutropenia developed in 31%.

Serious adverse reactions occurred in 46% of patients. Serious infections developed in 21% of patients, most commonly pneumonia (9%).

Due to rapid reduction in tumor volume, tumor lysis syndrome (TLS) is an important identified risk with venetoclax treatment. See the prescribing information for

***(Venclexta—AbbVie, Genentech)***

**FDA approves new drug for CLL or SLL, with or without 17 p deletion, after one prior therapy**

TLS risk stratification, prophylaxis, and monitoring.

All approved venetoclax regimens begin with a 5-week ramp-up. Full prescribing information is available at [Venclexta PI](#).

**Source URL:**

<http://aphadruginfoline.com/new-drug-approvals/fda-approves-new-drug-cll-or-sll-or-without-17-p-deletion-after-one-prior-therapy>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.